ABBV Earnings Prediction
The chart below shows how ABBV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ABBV sees a -1.62% change in stock price 10 days leading up to the earnings, and a +0.28% change 10 days following the report. On the earnings day itself, the stock moves by +0.66%. This data can give you a slight idea of what to expect for the next quarter's release.
ABBV Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
15.10B
5.60%
4.44%
Gross Margin
70.89%
17.60%
0.03%
Operating Margin
30.98%
21.73%
12.37%
Net Margin
-0.15%
-102.60%
-101.39%
EPS
-0.02
-104.35%
-102.27%
No Data Available
ABBV Earnings Analysis
AbbVie Inc Corporation (ABBV.N) Earnings Conference Call
Positive
Earnings Per Share Surge: Full year adjusted earnings per share reached $10.12, exceeding initial guidance by $0.49, demonstrating strong financial performance.
Revenue Surpasses Guidance: Total net revenues for the year were $5.63 billion, surpassing initial guidance by over $2 billion, reflecting a 4.6% operational growth despite significant HUMIRA erosion.
Sales Growth Acceleration: The ex HUMIRA platform achieved over 18% sales growth for the year, accelerating to 22% in the fourth quarter, indicating robust market performance.
Projected Revenue Surge: SKYRIZI and RINVOC are projected to generate nearly $24 billion in revenue for 2025, reflecting an increase of over $6 billion from previous estimates, driven by strong market capture.
Neuroscience Sales Growth: The neuroscience segment is expected to deliver $10 billion in sales for 2025, reflecting a $1 billion increase year-over-year, showcasing strong growth across key therapeutic areas.
Negative
HUMIRA Sales Decline: Total HUMIRA sales declined by 48.7% on an operational basis, primarily due to increased biosimilar competition, resulting in a significant revenue loss.
Aesthetics Sales Decline: Aesthetics segment reported a global sales decline of approximately 4.4%, with U.S. sales down 5%, attributed to challenging market conditions and suppressed consumer spending.
Imbruvica Revenue Decline: IMBRUVICA global revenues decreased by 6.2%, reflecting continued competitive dynamics in chronic lymphocytic leukemia (CLL), indicating pressure on this key oncology product.
Aesthetics Market Decline: The aesthetics market in China faced economic headwinds, contributing to a 3.2% operational decline in international aesthetics sales, highlighting vulnerability in key markets.
Operating Margin Impact: The adjusted operating margin ratio was impacted by a 10.4% unfavorable effect from acquired IP R&D expenses, indicating increased costs affecting profitability.
